Edgewood Oncology reveals encouraging outcomes from a research-driven trial for BTX-A51 in early tests on liposarcoma models.

An immunosuppressant is a type of medication that suppresses or reduces the strength of the immune system.

Alnylam Unveils Encouraging Outcomes from Phase 2 KARDIA-2 Trial with Zilebesiran on Top of Usual Hypertension Medications in Subjects with Poorly Managed High Blood Pressure.

Drug stability testing is a critical part of pharmaceutical development that assesses the physical, chemical, and microbiological stability of a drug product under various storage conditions over time.

Recent insights reveal that supplementing standard statin treatment with semi-annual doses of Leqvio® (inclisiran) can markedly decrease bad cholesterol levels in individuals with atherosclerotic cardiovascular disease in practical healthcare situations.

Herbal medicine preparation refers to the process of transforming plant materials—such as leaves, flowers, seeds, roots, and bark—into forms that can be used for therapeutic purposes.

Ocugen Reports Encouraging Results and DSMB Assessment, Launches Participant Recruitment for Intermediate Dosage Trial of OCU410, a Genetic Treatment Option, in Early-Stage ArMaDa Research Targeting Geographic Atrophy.

Microparticle technology refers to the creation and application of tiny particles with diameters ranging from a few nanometers to a few micrometers.

Cidara Therapeutics uses its Cloudbreak technology to develop novel drug-Fc conjugates. The company will showcase four posters at the AACR Annual Meeting.

4.1-4.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Adcentrx Therapeutics will showcase early-stage findings of their Nectin-4 antibody-drug conjugate (ADC) initiative at the 2024 AACR Annual Convention.

AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma: Airsupra Approval and Its Implications for Treatment.